Terms: = Lung cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS
493 results:
1. Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer.
Liu R; Huang X; Yang S; Du W; Chen X; Li H
Front Immunol; 2024; 15():1364506. PubMed ID: 38571938
[TBL] [Abstract] [Full Text] [Related]
2. Rolapitant treats lung cancer by targeting deubiquitinase OTUD3.
Du T; Gu Q; Zhang Y; Gan Y; Liang R; Yang W; Lu Y; Xu C; Wu J; Ma R; Cao H; Jiang J; Wang J; Feng J
Cell Commun Signal; 2024 Mar; 22(1):195. PubMed ID: 38539203
[TBL] [Abstract] [Full Text] [Related]
3. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
Xiaoxu D; Min X; Chengcheng C
BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
[TBL] [Abstract] [Full Text] [Related]
4. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract] [Full Text] [Related]
5. XAF1 overexpression inhibits the malignant progression and cisplatin resistance of NSCLC by activating endoplasmic reticulum stress.
Chen B; Cheng Y; Wu H; Yao J
Mol Biol Rep; 2024 Mar; 51(1):435. PubMed ID: 38520543
[TBL] [Abstract] [Full Text] [Related]
6. An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure.
Liu W; You W; Lan Z; Ren Y; Gao S; Li S; Chen WW; Huang C; Zeng Y; Xiao N; Wang Z; Xie H; Ma H; Chen Y; Wang G; Chen C; Li H
Cell Rep Med; 2024 Mar; 5(3):101448. PubMed ID: 38458196
[TBL] [Abstract] [Full Text] [Related]
7. Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
Lin Y; Cao Q; Hong A; Liang X
Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
[TBL] [Abstract] [Full Text] [Related]
8. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G; Pillozzi S; Antonuzzo L
Cancer Res; 2024 Apr; 84(8):1199-1209. PubMed ID: 38381540
[TBL] [Abstract] [Full Text] [Related]
9. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract] [Full Text] [Related]
10. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Malignant Lymphoma of the Bile Duct Mimicking Cholangiocarcinoma].
Saeki S; Tokumitsu Y; Shindo Y; Matsui H; Nakajima M; Kimura Y; Iida M; Suzuki N; Takeda S; Ioka T; Nagano H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1627-1629. PubMed ID: 38303363
[TBL] [Abstract] [Full Text] [Related]
12. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.
Wang D; Huang L; Qian D; Cao Y; Wu X; Xu P; Ming L; Tang J; Huang Z; Yin Y; Zhou L
Front Immunol; 2023; 14():1334408. PubMed ID: 38259481
[TBL] [Abstract] [Full Text] [Related]
13. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract] [Full Text] [Related]
14. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review.
Hong G
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247
[TBL] [Abstract] [Full Text] [Related]
15. Activin A induces apoptosis of human lung adenocarcinoma A549 cells through endoplasmic reticulum stress pathway.
Zhang F; Qi Y; Li J; Liu B; Liu Z; Cui X
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38131250
[TBL] [Abstract] [Full Text] [Related]
16. Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature.
Bradová M; Mosaieby E; Michal M; Vaněček T; Ing SK; Grossmann P; Koshyk O; Kinkor Z; Laciok Š; Nemcová A; Straka Ľ; Farkas M; Michal M; Švajdler M
Histopathology; 2024 Apr; 84(5):776-793. PubMed ID: 38114270
[TBL] [Abstract] [Full Text] [Related]
17. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract] [Full Text] [Related]
18. Tannins in Phyllanthus emblica L. improves cisplatin efficacy in lung cancer cells by boosting endoplasmic reticulum stress to trigger immunogenic cell death.
Hu Q; Wang S; Cheng R; Liu Y; Chang Z; Huang Y; Chen Y; Luo X; Zhou L; Wang B; Gao Y; Chen H; Liu R; Zhang L
Phytomedicine; 2024 Jan; 123():155219. PubMed ID: 38056150
[TBL] [Abstract] [Full Text] [Related]
19. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
Namkaew J; Zhang J; Yamakawa N; Hamada Y; Tsugawa K; Oyadomari M; Miyake M; Katagiri T; Oyadomari S
Cancer Lett; 2024 Feb; 582():216509. PubMed ID: 38036042
[TBL] [Abstract] [Full Text] [Related]
20. Current diagnosis and treatment of salivary gland-type tumors of the lung.
Horio Y; Kuroda H; Masago K; Matsushita H; Sasaki E; Fujiwara Y
Jpn J Clin Oncol; 2024 Mar; 54(3):229-247. PubMed ID: 38018262
[TBL] [Abstract] [Full Text] [Related]
[Next]
